Op2Lysis

Op2Lysis is a promising startup in the medical field, focusing on developing treatments for thrombosis at the cerebrovascular level, with a particular emphasis on hemorrhagic stroke – an area with a current lack of approved therapeutic solutions. The company is working on its innovative NANOp2Lysis platform, which integrates breakthrough vectorisation technology, industrial expertise for clinical quality production, and preclinical proficiency to offer predictive and translational models - a pioneering endeavor in this sector. Their flagship product O2L-001, derived from this groundbreaking technology, is on the verge of entering regulatory toxicology, marking a significant stride toward seeking clinical trial authorization in North America and Europe. Founded in 2016, Op2Lysis has attracted attention with its slogan "A New Hope for Hemorrhagic Stroke," and the progress it has made in the development of much-needed medical interventions. This startup presents an intriguing investment opportunity for venture capitalists seeking to support game-changing innovations in the healthcare industry.